CAR-T (T-cells expressing Chimeric Antigen Receptors) therapy has displayed significant success in treating patients with otherwise incurable B-cell lymphomas. The field is rapidly expanding to include new disease indications and CAR designs. CAR-T adoption, however, is not without challenges. The industry needs to learn as quickly as possible about all aspects of CAR-T.

The Center for Blood and Marrow Transplant Research (CIBMTR) has expanded to capture CAR-T data for research purposes. Four new CAR-T forms have been created that can be electronically submitted. Six forms originally created for HCT have been modified to include CAR-T data. CIBMTR supports electronic form submission via its AGNIS interface.